Algernon Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGNPF research report →
About the company
Algernon Pharmaceuticals Inc. is a biopharmaceutical firm actively engaged in drug development at the clinical trial stage. Its therapeutic endeavors span a range of challenging medical conditions, including non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), persistent cough, and acute lung damage linked to COVID-19, with operations primarily in Canada and Australia.
- CEO
- Christopher J. Moreau
- IPO
- 2016
- Employees
- 5
- HQ
- Vancouver, BC, CA
Price Chart
- Revenue
- $0 · 0.00%
- Net Income
- $-1,715,892 · -241.13%
- EPS
- $-0.58 · -131.87%
- Op Income
- $-1,716,631
- FCF YoY
- 58.61%
- 52W High
- $0.64
- 52W Low
- $0.23
- 50D MA
- $0.31
- 200D MA
- $0.41
- Beta
- 0.91
- Avg Volume
- 11.98K
Get TickerSpark's AI analysis on AGNPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AGNPF coverage
Recent articles, reports, and earnings notes.
No research on AGNPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGNPF report →Similar companies
Peers in the same neighborhood.